[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evommune Inc (EVMN)

Evommune Inc (EVMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 710,635
  • Shares Outstanding, K 36,018
  • Annual Sales, $ 13,000 K
  • Annual Income, $ -68,870 K
  • EBIT $ -45 M
  • EBITDA $ -80 M
  • 60-Month Beta N/A
  • Price/Sales 54.91
  • Price/Cash Flow N/A
  • Price/Book 2.34

Options Overview Details

View History
  • Implied Volatility 157.46% (-0.92%)
  • Historical Volatility 59.67%
  • IV Percentile 41%
  • IV Rank 61.44%
  • IV High 199.05% on 05/07/26
  • IV Low 91.19% on 05/15/26
  • Expected Move (DTE 14) 0.00 (0.00%)
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 121
  • Open Int (30-Day) 72
  • Expected Range 20.90 to 20.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 6
  • High Estimate $-0.57
  • Low Estimate $-0.76
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.54 +6.35%
on 06/03/26
24.90 -16.55%
on 05/08/26
-2.85 (-12.06%)
since 05/04/26
3-Month
19.54 +6.35%
on 06/03/26
29.07 -28.52%
on 04/21/26
-2.81 (-11.91%)
since 03/04/26

Most Recent Stories

More News
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ...

EVMN : 20.72 (+5.02%)
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26

EVMN : 20.72 (+5.02%)
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data...

EVMN : 20.72 (+5.02%)
Evommune Announces $125 Million Private Placement

Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today...

EVMN : 20.72 (+5.02%)
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo ...

EVMN : 20.72 (+5.02%)
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 20.72 (+5.02%)
ATAI : 4.48 (-1.10%)
CRMD : 8.61 (+4.62%)
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized...

EVMN : 20.72 (+5.02%)
Evommune Announces Pricing of its Initial Public Offering

PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...

EVMN : 20.72 (+5.02%)
Evommune Announces Commencement of Initial Public Offering

PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...

EVMN : 20.72 (+5.02%)

Business Summary

Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 20.61
2nd Resistance Point 20.36
1st Resistance Point 20.05
Last Price 20.72
1st Support Level 19.48
2nd Support Level 19.22
3rd Support Level 18.91

See More

52-Week High 33.20
Fibonacci 61.8% 25.82
Fibonacci 50% 23.54
Fibonacci 38.2% 21.26
Last Price 20.72
52-Week Low 13.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.